A long-term study of young patients with essential thrombocythemia treated with anagrelide

Hematology Department of Biocellular Technology and Hematology, La SapienzaUniversity, Rome, Italy. mazzucconi@bce.med.uniroma1.it BACKGROUND AND OBJECTIVES: Essential thrombocythemia (ET) can be complicated by life-threatening thrombosis and has a risk of converting into acute leukemia. Cytoreducti...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 89; no. 11; pp. 1306 - 1313
Main Authors Mazzucconi, MG, Redi, R, Bernasconi, S, Bizzoni, L, Dragoni, F, Latagliata, R, Santoro, C, Mandelli, F
Format Journal Article
LanguageEnglish
Published Pavia Haematologica 01.11.2004
Subjects
Adult
Anemia - chemically induced
Biological and medical sciences
Female
Hematologic and hematopoietic diseases
Hemoglobins - analysis
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Platelet diseases and coagulopathies
Quinazolines - adverse effects
Quinazolines - therapeutic use
Stomach Diseases - chemically induced
Tachycardia - chemically induced
Thrombocythemia, Essential - drug therapy
Time Factors
Human
leukemic transformation
Hematology
Quinazoline derivatives
Leukemia
Cardiovascular disease
Malignant hemopathy
Essential
Long term
Thrombosis
Anagrelide
Vascular disease
Thrombocythemia
Myeloproliferative syndrome
Treatment
essential thrombocythemia
Online AccessGet full text

Cover

More Information
Summary:Hematology Department of Biocellular Technology and Hematology, La SapienzaUniversity, Rome, Italy. mazzucconi@bce.med.uniroma1.it BACKGROUND AND OBJECTIVES: Essential thrombocythemia (ET) can be complicated by life-threatening thrombosis and has a risk of converting into acute leukemia. Cytoreductive therapy may reduce the risk of thromboembolic complications. Herein, we report the results of a long-term study of patients with ET treated with anagrelide to control thrombocytosis. DESIGN AND METHODS: Thirty-nine (34 evaluable) patients (median age, 33 years; 24 previously untreated) were enrolled between 1989-1996; the mean platelet count prior to therapy was 1197x10(9)/L. Only 9 out of 34 evaluable patients were at high risk of thrombosis (platelet count more than 1500x10(9)/L). The initial dose of anagrelide (0.5 mg/bid for 7 days) was increased by 0.5 mg/day (maximum dose: 3 mg/day) until a response was seen. RESULTS: A complete response (platelets
ISSN:0390-6078
1592-8721